.
.
.
.

Coronavirus: AstraZeneca resumes COVID-19 vaccine trial after UK green light

Published: Updated:

British clinical trials for the AstraZeneca and Oxford University coronavirus vaccine have resumed following confirmation by the Medicines Health Regulatory Authority (MHRA) that it was safe to do so, the company said on Saturday.

The late-stage trials of the experimental vaccine, one of the most advanced in development, were suspended this week after an illness in a study subject in Britain.

For more coronavirus news, visit our dedicated page.

“The standard review process triggered a voluntary pause to vaccination across all global trials to allow review of safety data by independent committees, and international regulators,” AstraZeneca said.

“The UK committee has concluded its investigations and recommended to the MHRA that trials in the UK are safe to resume.”

For all the latest headlines, follow our Google News channel online or via the app.

The company said it could not disclose further medical information.

“All trial investigators and participants will be updated with the relevant information and this will be disclosed on global clinical registries, according to the clinical trial and regulatory standards.”

Read more:

Why did AstraZeneca pause its trials and what it means for the COVID-19 vaccine race?

Coronavirus vaccine trials should be successful by end of 2020: AstraZeneca CEO

Coronavirus: Kids can spread infection just like adults, new study shows